Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors-Reference-Cited by-同舟云学术

Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors

Published:2024-04-23 Issue: Volume: Page:
ISSN:1932-2259
Container-title:Journal of Cancer Survivorship
language:en
Short-container-title:J Cancer Surviv

Author:

Lammers Eline M. J.,Nijdam Annelies,Zijlstra Josée M.,Janus Cécile P. M.,de Weijer Roel J.,Appelman Yolande,Manintveld Olivier C.,Teske Arco J.,van Leeuwen Flora E.,Aleman Berthe M. P.

Funder

ZonMw

KWF Kankerbestrijding

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11764-024-01561-y.pdf

Reference32 articles.

1. Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450–9. https://doi.org/10.1038/nrclinonc.2012.91.

2. Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv19–29. https://doi.org/10.1093/annonc/mdy080.

3. Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209–15. https://doi.org/10.1053/j.seminhematol.2016.05.008.

4. de Vries S, Schaapveld M, van Nimwegen FA, Jozwiak K, Lugtenburg PJ, Daniels LA, et al. High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors. Br J Cancer. 2018;118(6):887–95. https://doi.org/10.1038/bjc.2017.476.

5. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van ’t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–86. https://doi.org/10.1182/blood-2006-07-034405.